Sapacitabine: Phase III ongoing

Cyclacel said an independent DSMB recommended continuation of the open-label, international Phase III SEAMLESS trial of oral sapacitabine based on available data from 317 patients

Read the full 257 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE